Reta Cagri Blend Dosage Chart: Research Ranges and Titration

There is no official reta cagri blend dosage chart, because no regulatory agency has approved a fixed-dose combination of retatrutide and cagrilintide for human use. What circulates online is a mix of single-agent trial data, compounded-peptide label instructions, and community logs. Treat every number below as a research reference point rather than a prescription.

Retatrutide (often shortened to "reta") and cagrilintide ("cagri") are investigational peptides sold for laboratory research only in the United States. Any human use is off-label, unregulated, and carries unknown risk.

What Is a Reta Cagri Blend?

Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors. Cagrilintide is a long-acting amylin analog that slows gastric emptying and signals fullness through a separate pathway. Because those mechanisms only partly overlap, researchers sometimes stack them.

The theory behind a blend is that a lower dose of each peptide might produce an effect comparable to a higher dose of one alone. That theory is plausible but unproven, and no randomized trial has tested the combination.

Most discussions of cagri reta blend dosage begin with the separate schedules used in retatrutide and cagrilintide monotherapy trials, then merge them into a single weekly plan.

Reta Cagri Blend Dosage Chart (Research Reference)

The chart below shows how a research protocol might scale a blend over twelve weeks. The ranges reflect published single-agent trials, not a tested combination.

Phase	Weeks	Retatrutide per week	Cagrilintide per week	Notes
Step 1 (start)	1–4	1–2 mg	0.25–0.6 mg	Lowest step; establish tolerability
Step 2	5–8	2–4 mg	0.6–1.2 mg	Advance only if step 1 was tolerated
Step 3	9–12	4–6 mg	1.2–2.4 mg	Common research range for cagrilintide
Maintenance	13+	6–12 mg	2.4 mg	No established combination ceiling

The upper ends of these ranges come from single-agent retatrutide trials that used up to 12 mg weekly and cagrilintide trials that reached 4.5 mg weekly. Combining those maximums has never been studied in humans.

How a Cagri Reta Blend Dosage Calculator Works

A cagri reta blend dosage calculator handles three tasks: converting milligrams into syringe units, splitting a weekly total across injection days, and tracking how long you have held each step.

Volume math is where most dosing mistakes happen. The formula is simple: dose in mg ÷ concentration in mg/mL = volume in mL.

Vial size	Diluent added	Concentration	1 mg draw	2 mg draw
5 mg	1 mL	5 mg/mL	0.2 mL (20 units)	0.4 mL (40 units)
10 mg	2 mL	5 mg/mL	0.2 mL (20 units)	0.4 mL (40 units)
10 mg	1 mL	10 mg/mL	0.1 mL (10 units)	0.2 mL (20 units)

Unit figures assume a U-100 insulin syringe. When the math lands between marks, round down rather than up.

Titration and Timing Rules

• Start at the lowest step and hold it for at least four weeks.
• Change only one variable at a time. If both peptides increase in the same week, you cannot tell which one caused a reaction.
• Inject subcutaneously into the abdomen, thigh, or upper arm, rotating sites each time.
• Treat a high-end reference such as a reta 15 mg dosage chart as a research ceiling, not a target to reach.
• Log body weight, resting heart rate, and gastrointestinal symptoms every week.

Reta + Cagri vs. Single-Agent Protocols

Protocol	Receptors targeted	Weekly research range	Evidence quality
Retatrutide alone	GLP-1, GIP, glucagon	1–12 mg	Phase 3 trials published
Cagrilintide alone	Amylin	0.25–4.5 mg	Phase 2 trials published
Reta + cagri blend	GLP-1, GIP, glucagon, amylin	1–6 mg + 0.25–2.4 mg	No combination trial
Cagrilintide + semaglutide	Amylin, GLP-1	2.4 mg + 2.4 mg	Phase 3 program

Reported Cagri Reta Blend Benefits in Research

Separate trials of retatrutide and cagrilintide have each shown average weight reduction in adults with obesity, plus improved blood sugar markers in participants with type 2 diabetes. Reported cagri reta blend benefits are extrapolated from those individual results.

Potential advantages discussed in research settings include appetite suppression through two pathways, slower gastric emptying, and the possibility of using smaller individual doses.

No published clinical trial has confirmed that combining retatrutide and cagrilintide improves outcomes compared with either peptide alone.

Other metabolic research compounds are often discussed in the same forums. A mots-c dosage chart, for example, follows an entirely different schedule because MOTS-c targets cellular energy metabolism rather than appetite signaling.

Reta Cagri Blend Side Effects and Safety

The most frequently reported reta cagri blend side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These often ease after a few weeks at a stable dose but tend to return with each increase.

Other reported issues include:

• Injection-site redness, itching, or small nodules
• Elevated resting heart rate
• Gallbladder disease, including gallstones
• Pancreatitis, which is rare but serious
• Hypoglycemia when used alongside insulin or sulfonylureas
• Loss of lean muscle mass alongside fat loss

GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors seen in rodents. People with a personal or family history of medullary thyroid carcinoma or MEN2 should avoid these compounds entirely.

Pregnancy and breastfeeding are absolute exclusions. Anyone considering a research peptide should speak with a licensed healthcare professional first.

Legal Status, Sourcing, and Storage

Retatrutide and cagrilintide are not FDA-approved for any human use. They are sold as research chemicals, and the FDA has issued warnings about compounded versions of related GLP-1 drugs.

Vendor purity varies widely, so a third-party certificate of analysis is the minimum documentation to request. Lyophilized powder should be stored at -20 °C or colder and protected from light.

After reconstitution with bacteriostatic water, most peptides remain stable for roughly four to six weeks refrigerated. Discard any vial that looks cloudy or contains visible particles.

Key Takeaways

• No approved reta cagri blend dosage chart exists; every posted protocol is experimental.
• Research protocols typically begin near 1–2 mg of retatrutide and 0.25–0.6 mg of cagrilintide per week.
• Titration should change one variable at a time, with at least four weeks held at each step.
• Gastrointestinal side effects are the most common reason people stop these peptides.
• Neither peptide is FDA-approved, and both are sold for research use only.

COMMON QUESTIONS

Frequently Asked Questions

Is there an official reta cagri blend dosage chart?

No. Neither retatrutide nor cagrilintide is FDA-approved for human use, and no clinical trial has tested the two peptides together. Charts posted online are assembled from single-agent trial data and anecdotal logs, so they should be treated as experimental rather than clinical guidance.

What is a typical starting dose for a reta cagri blend?

Research protocols commonly begin around 1–2 mg of retatrutide and 0.25–0.6 mg of cagrilintide per week, holding that step for roughly four weeks before any increase. Lower starting amounts are often used when tolerability is a concern. There is no validated starting dose because the combination has never been studied in a controlled trial.

What side effects are reported with retatrutide and cagrilintide blends?

Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation are the most commonly reported effects, along with injection-site reactions and a higher resting heart rate. More serious risks include gallbladder disease, pancreatitis, hypoglycemia when combined with insulin or sulfonylureas, and loss of lean muscle mass. GLP-1 drugs also carry a boxed warning about thyroid C-cell tumors observed in rodents.